Related Experiment Video
Updated: Jun 10, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Genetic analysis of chemoresistance in primary murine lymphomas
C A Schmitt1, C T Rosenthal, S W Lowe
1Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA.
Abstract:
Understanding the basis of chemoresistance is a principal goal of molecular oncology. We have exploited a murine lymphoma model and retroviral gene transfer to rapidly generate a series of spontaneous tumors differing only in a gene of interest, and subsequently studied the impact of the test gene on the treatment sensitivity of tumors at their natural site. We demonstrate that the Bcl-2 oncoprotein produces multi-drug resistance when assessed in primary lymphomas in vivo. In contrast, this effect was dramatically reduced when the primary lymphomas were subjected to long-term culture, and completely missed in the standard clonogenic survival assay. This model highlights the importance of physiological test systems to address the complexity of clinical drug resistance and provides a novel strategy to evaluate compounds targeting specific genetic lesions.
Insights
The Bcl-2 oncoprotein causes multi-drug resistance in primary lymphomas. Physiological test systems are crucial for studying drug resistance, unlike standard assays which may miss these effects.
Area of Science:
- Molecular oncology
- Cancer biology
- Drug discovery
Background:
- Chemoresistance is a major challenge in cancer treatment.
- Understanding the genetic basis of chemoresistance is critical for developing effective therapies.
- Existing models may not accurately reflect in vivo drug response.
Purpose of the Study:
- To investigate the role of the Bcl-2 oncoprotein in chemoresistance in primary lymphomas.
- To evaluate the utility of a murine lymphoma model for studying drug sensitivity in vivo.
- To compare the efficacy of different experimental systems in detecting drug resistance.
Main Methods:
- Utilized a murine lymphoma model with retroviral gene transfer to create tumors with specific genetic differences.
- Assessed the impact of the Bcl-2 oncoprotein on tumor treatment sensitivity in vivo.
- Compared results from in vivo studies with long-term culture and clonogenic survival assays.
Main Results:
- The Bcl-2 oncoprotein conferred multi-drug resistance in primary lymphomas in vivo.
- This chemoresistance effect was significantly reduced in lymphomas subjected to long-term culture.
- The effect of Bcl-2 oncoprotein-induced resistance was not detected in standard clonogenic survival assays.
Conclusions:
- The Bcl-2 oncoprotein is a key mediator of multi-drug resistance in primary lymphomas.
- Physiological in vivo models are essential for accurately assessing clinical drug resistance.
- This study presents a novel strategy for evaluating compounds targeting genetic lesions in cancer therapy.
